Engineering monoclonal antibodies for COVID-19 prophylaxis.

ABSTRACT: The therapeutic and prophylactic uses of monoclonal antibodies (mABs) against SARS-CoV-2 are limited by their short half-life and need for intravenous delivery. In this issue, Cobb et al.¹ engineer a neutralizing mAB cocktail with extended half-life that can be delivered intramuscularly to provide prophylactic protection against infection in rhesus macaques.

SUBMITTER: Izadpanah A 

PROVIDER: S-EPMC8915435 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature